Nifoxipam

Nifoxipam is a designer benzodiazepine and an analog of flunitrazepam (Rohypnol), differing by the addition of a hydroxyl group at the 3-position. It belongs to the nitrobenzodiazepine subclass — characterized by a nitro group at the 7-position of the benzene ring — and produces pronounced sedation, sleep promotion, and anxiolysis. Nifoxipam has been characterized as producing stronger tranquilizing and sleep-prolonging effects than lormetazepam, with a lower LD50 in animal models than both lormetazepam and flunitrazepam, suggesting potentially lower acute toxicity in laboratory settings.

Nifoxipam emerged in research chemical markets as a less scrutinized alternative to flunitrazepam, which had become heavily regulated following its association with drug-facilitated sexual assault. The structural relationship to flunitrazepam — sharing the nitrobenzodiazepine scaffold and its associated amnestic properties — raises harm reduction concerns similar to those for the parent compound, particularly in social contexts where covert administration is a risk.

The pharmacological profile of nifoxipam is not extensively characterized. Available animal and limited pharmacological data suggest a compound profile weighted toward sedation and hypnosis over anxiolysis, consistent with the 3-hydroxy substitution pattern seen in other hypnotic benzodiazepines (e.g., lormetazepam, temazepam). Community experience with nifoxipam is limited in the database, reflecting its niche position in the designer benzodiazepine market.